An update from InspireMD ( (NSPR) ) is now available.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
InspireMD, Inc. announced on October 7, 2024, the FDA approval to begin the CGUARDIANS II pivotal study for their CGuard Prime 80cm Carotid Stent System. This milestone is a significant step for the company, aiming to enhance stroke prevention and carotid disease management. The study, led by esteemed vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck, will evaluate the device’s use during transcarotid revascularization procedures. This approval propels InspireMD towards its goal of market leadership in the U.S. and global expansion, while concurrently developing their next-generation TCAR Neuroprotection System, SwitchGuard NPS.
For detailed information about NSPR stock, go to TipRanks’ Stock Analysis page.
